Hackensack Meridian San Antonio Breast Cancer Review 2024
- Free Shipping on orders over 45$
- In stock, ready to ship
- Inventory on the way
Hackensack Meridian San Antonio Breast Cancer Review 2024
+ Include: 1 videos, size: 2.84 GB+ Target Audience: medical, surgical, and radiation oncologists; breast imaging specialists; oncology pharmacists
+ Information:
A concise, case-based update distilling the most practice-changing findings from the San Antonio Breast Cancer Symposium (SABCS). Faculty translate new trial data and guidelines into clear diagnostic and therapeutic pathways for clinic and tumor board.
What You Will Learn
-
How to integrate recent evidence into screening, staging, and biomarker-driven treatment
-
Selection and sequencing of systemic therapy across HR+, HER2+, and triple-negative disease
-
Practical use of genomic assays, residual disease tools, and MRD/ctDNA where applicable
-
Toxicity prevention and management for targeted agents and immunotherapies
-
Survivorship care plans: bone health, fertility, cardiometabolic risk, and symptom control
Event Details
-
Format: Focused lectures, case panels, and interactive Q&A with take-home checklists
-
Structure: Disease-subtype blocks plus cross-cutting sessions on imaging, surgery/radiation, and supportive care
-
Access: Built for rapid implementation in community and academic settings
Who Should Attend
Medical, surgical, and radiation oncologists; breast imaging specialists; oncology pharmacists and nurses; advanced practice providers; tumor-board members; fellows/trainees.
Why Attend
-
Convert fresh SABCS data into simple, actionable algorithms
-
Align multidisciplinary decisions across surgery, radiation, and systemic therapy
-
Improve patient experience with clear counseling scripts and follow-up pathways
*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the below
-
HR+ disease: endocrine backbones, CDK4/6 use, escalation/de-escalation strategies
-
HER2+ disease: neoadjuvant/adjuvant choices, antibody–drug conjugates, brain metastasis considerations
-
Triple-negative: chemo–IO combinations, ADCs, germline/somatic targeting
-
Genomics & biomarkers: assays for prognosis/prediction, ctDNA/MRD concepts, pathology reporting pearls
-
Local therapy: surgical margins, axillary management, radiation indications and partial-breast options
-
Supportive care: toxicity mitigation, bone/cardiac health, fertility and menopause management, survivorship
- Orders under 45$ will have a shipping charge of a flat rate of 15$.
-Orders over 45$ will have Free Shipping.